Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): A randomised, multicentre, open-label, phase 4 study - Jackson, D J; Heaney, L G; Humbert, M; SHAMAL Investigators (Lancet, 2024)
(10423):